Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Russia
  4. Moscow Micex - RTS
  5. Sberbank
  6. News
  7. Summary
    SBER   RU0009029540

SBERBANK

(SBER)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sberbank of Russia : to help implement Russia's pharmaceutical industry development strategy

10/19/2020 | 09:05am EDT

Sberbank has signed a cooperation agreement with JSC Pharmasyntez, a pharmaceutical leader in Russia. The agreement was inked by Anatoly Popov, Deputy Chairman of the Executive Board at Sberbank, and Vikram Punia, President of Pharmasyntez.

The parties have agreed to join their effort in developing the pharmaceutical industry in Russia in line with the Pharma 2030 development strategy. The agreement covers interaction in multiple areas, including co-investment, debt and equity finance, long-term financing of Pharmasyntez projects, digitization and streamlining of its production, and the adoption of new technology.

Anatoly Popov, Deputy Chairman of the Executive Board, Sberbank:

'We've been working with Pharmasyntez for years across a wide range of issues. It's our long-standing customer and a reliable partner with high innovative potential. Earlier, we had approved a RUB15 bln lending limit for the company. The agreement we've signed today and our growing partnership will ensure an increase in the exportation of medications and the introduction of innovations into production while also helping to accelerate the development of this strategically important industry, which has people's lives depending on its continuous operation.'

Vikram Punia, President of Pharmasyntez Group of Companies:

'Sberbank has been our strategic financial partner for years. Combining the efforts of Pharmasyntez and Sberbank will contribute to the modernization of production with the introduction of advanced technology and the formation of a stable innovation foundation for Pharmasyntez. The attracted investment and the introduction of new technology will be used to conduct clinical trials of candidate drugs in Russia and abroad and to develop investment activities, as well as to ensure high growth rates for Pharmasyntez Group until 2025.'

Disclaimer

Sberbank of Russia published this content on 19 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2020 13:04:09 UTC


© Publicnow 2020
All news about SBERBANK
06/16SBERBANK  : services named best for SMEs
PU
06/16SBERBANK  : Sber awarded for innovations in digitalization of social sphere
PU
06/16SBERBANK  : Sber to reinforce Okko's positions by engaging sports fans
PU
06/16SBERBANK  : Charitable Foundation Investment to the Future partners with MGPU, H..
PU
06/16SBERBANK  : Sber proposes solutions for IT industry growth at Sviaz 2021
PU
06/16AFTER WORK : over half of Russians want to save for retirement with their employ..
PU
06/16SBERINDEX : Russians spend less, eat more
PU
06/16SBERBANK  : on mortgage borrowers who buy single-family homes in Russia
PU
06/15SISTEMA PJSFC  : Sistema announces financial -4-
DJ
06/11SBERBANK  : Sber escrow accounts surpass 1 trillion rubles
PU
More news
Financials
Sales 2021 2 428 B 33 505 M 33 505 M
Net income 2021 1 014 B 13 989 M 13 989 M
Net Debt 2021 - - -
P/E ratio 2021 6,77x
Yield 2021 7,60%
Capitalization 7 049 B 97 956 M 97 266 M
Capi. / Sales 2021 2,90x
Capi. / Sales 2022 2,67x
Nbr of Employees 278 165
Free-Float 45,3%
Chart SBERBANK
Duration : Period :
Sberbank Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SBERBANK
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 374,91 RUB
Last Close Price 313,06 RUB
Spread / Highest target 53,3%
Spread / Average Target 19,8%
Spread / Lowest Target -1,30%
EPS Revisions
Managers and Directors
NameTitle
Herman Gref Chief Executive Officer & Member-Supervisory Board
Alexandra Buriko Chief Financial Officer & Head-Finance
Anton Germanovich Siluanov Chairman-Supervisory Board
David Rafalovsky Chief Technology Officer & Executive VP
Larisa A. Zalomikhina Director-Compliance Department
Sector and Competitors